Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
With the Community Pharmacist Consultation Service (CPCS) now bedding in, below you will find a selection of questions about the service which PSNC has been asked by LPCs and pharmacy teams over the last few weeks. View all our frequently asked questions on the CPCS Q. Will there be a training programme for CPCS? As...
Issued: 14 November 2019 The Department of Health and Social Care (DHSC) have advised that Synphase tablets are out of stock until 20 December 2019. Other brands of phasic oral contraceptive tablets remain available during this period. Action required: For patients without sufficient supplies of Synphase® tablets to last until the resolution date, prescribers may:...
MSN/2019/007U, update to SDA/2019/002 Date issued 14th November DHSC have advised that Mylan, the sole supplier of disopyramide 150mg capsules, has had a delay to their resupply date. Mylan will be out of stock of Disopyramide 150mg capsules to approximately 13th December 2019. Supplies are available from specialist importers on an ‘unlicensed’ basis. Ensure that...
MSN/2019/008U Date issued: 14/11//2019 Pfizer, the sole supplier of Provera tablets, are experiencing manufacturing delays, and are out of stock of the 100mg and 200mg tablets. Resupply of Provera 100mg tablets is delayed until 13th December 2019 Provera 200mg tablets are now out of stock until 20th December 2019 Provera 400mg tablets are available, but...
Issued: 14 November 2019 The Department of Health and Social Care (DHSC) have advised that Pethidine 50mg tablets will be out of stock until early December 2019. Teva and Martindale are out of stock of pethidine 50mg tablets There are no alternative suppliers. Teva anticipate resupply week commencing 2nd December 2019 and Martindale in mid-December...
SDA/2019/008 Issued: 14 November 2019 The Department of Health and Social Care (DHSC) have advised that Minims phenylephrine 2.5% and 10% w/v eye drops will be out of stock from the end of November 2019 until early January 2020. Bausch and Lomb are experiencing supply issues across their phenylephrine Minims range. Action required: Specialist importer...
The October 2019 edition of PSNC’s Community Pharmacy News (CPN) is now available. This month’s CPN features: CPCS goes live; Five-year CPCF implemented; PSNC annual report; and SSPs for Fluoxetine capsules. View our CPN magazine online via the flipbook reader below or download the PDF copy. Please note, the colour PDF can be printed out...
Community pharmacy contractors are reminded of the Pharmacy Quality Scheme (PQS) gateway criterion to edit or validate their NHS website entry for their pharmacy and to edit or confirm their Directory of Services (DoS) profile to meet the DoS quality criterion of the Digital enablers domain by 11.59pm on 30th November 2019. The latest data...
With the Community Pharmacist Consultation Service (CPCS) now bedding in, below you will find a selection of questions about the service which PSNC has been asked by LPCs and pharmacy teams over the last few weeks. View all our frequently asked questions on the CPCS Q. Will I receive all referrals via the CPCS IT...
Further to our news story Temporary parallel export ban issued to ensure continued supply of medicines the Department of Health and Social Care (DHSC) and the Medicines and Healthcare products Regulatory Agency (MHRA) has announced that Hepatitis A and B vaccine are to be added to the list of medicines which must not be parallel exported...
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
Sets out medicines that cannot be parallel exported from the UK because they are needed for UK patients.
Marketing authorisations granted in October 2019
Parallel import licenses granted in October 2019
Guidance on how to get an e-cigarette on the market in the UK, including the notification scheme and reporting problems with e-cigarettes.
List of field safety notices (FSNs) from medical device manufacturers from 04 to 08 November 2019
Sandoz Limited is recalling one batch due to the occurrence of degradation in some vials, resulting in green discoloration of the powder in the vial, leading to increased levels of impurities/degradation products in the medicine.
This recall affects Mitomycin-C Kyowa 2 mg (PL 16508/0042), 10 mg (PL 16508/0043), 20 mg (PL 16508/0044), powder for solution for injection, and Mitomycin-C Kyowa 40 mg (PL 16508/0045), powder for intravesical solution.
Medicines and Healthcare products Regulatory Agency (MHRA) good manufacturing practice (GMP) deficiencies since April 2010.
M & A Pharmachem is recalling specific batches as a precautionary measure, because a small number of pots from some batches have been found to contain discoloured tablets due to fungal contamination
List of field safety notices (FSNs) from medical device manufacturers from 28 October to 1 November 2019.
Medicines that were granted a positive opinion under the early access to medicines scheme (EAMS) which has now expired.
List of sites granted a manufacturer or wholesale dealer licence
List of companies in the UK who have their licence to manufacture or wholesale medicines terminated and cancelled.
Current listing of UK brokers authorised to broker human medicines, including company name, registration and address.
Department of Health and Social Care and MHRA register of licensed wholesale distribution sites (human and veterinary).
Department of Health and MHRA register of licensed manufacturing sites - manufacturer specials (human) (MS) and manufacturer specials authorisation (veterinary) (MANSA) only.
EAMS scientific opinion given to Merck Serono Ltd in the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
Information about the risks of taking valproate medicines during pregnancy.
This privacy notice describes how we collect and use your personal information, in accordance with the Data Protection Act and the General Data Protection Regulation.
Reporting against VMD published standards up to 31 October 2019.
Details of seizure notice issued to Pawfection Pets, Abertillery, Wales.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
Start using the new @vmd.gov.uk email address now.
Guidance on applying for an authorisation to manufacture veterinary medicines.
Marketing Authorisations Information Service (MAVIS) Hub edition 112
This report (UK VARSS) provides the details of UK veterinary antibiotic resistance and sales surveillance.
This is the hub for all the Veterinary Medicines Directorate's communications on Brexit which includes guidance on how you can prepare.
This report (UK VARSS) provides the details of UK veterinary antibiotic resistance and sales surveillance.
New VARSS report confirms that sales of veterinary antibiotics have halved over the past four years.
This report (UK VARSS) provides the details of UK veterinary antibiotic resistance and sales surveillance.
Details of seizure notice served to Meadowbrook Equine Clinic, Luton, Bedfordshire.
How to comply with the exemption from the Veterinary Medicines Regulations that allow certain animal medicines to be sold without an authorisation.
National Office of Animal Health: Animal Health – are you ready for Brexit?
Availability of flunixin solutions for injection.
Report of the ten products for which most Special Import and Special Treatment Certificates (SIC and STC) have been issued by VMD in the UK.
Re-certification to ISO 9001 and ISO 27001 standards following audit.
Launch of national application forms for a marketing authorisation.
Availability of veterinary medicines after Brexit.
As a vet or pharmacist, you must follow legal requirements when working with controlled drugs in veterinary medicine.
The study team will review how current health and social care systems work.
The company has also submitted a marketing authorisation application for the drug to the European Medicines Agency.
Last night the annual awards ceremony for the Marketer of the Year, Communications Team of the Year & Sales competitions took place at the gorgeous Chelsea Harbour Hotel.
The therapy, a once-daily oral medicine, was initially approved in the US in May 2019 under the name Qternmet XR.
The organisation updates its MS Guideline to state that Sativex should be offered to treat spasticity in people with the disorder.
The study is the sixth Phase III trial of the drug’s programme.
Only one drug has been approved for the indication in the lat 60 years, GlaxoSmithKline’s Benlysta (belimumab), which was also the first-ever biologic treatment for the disease.
More than half of the public are not aware the condition may be preventable, and just under half are unaware of the steps that can be taken to prevent or delay the development of the condition.
The impact of chronic hepatitis B treatment on hepatocellular carcinoma incidence was evaluated in a long-term analysis of the Gilead drug.
Now celebrating its 10th anniversary, The Clinical Researcher of the Year – The Americas has opened its doors for entry.
The study was the first randomised trial to test the abdominal stitch in this group of women.
42.2% of non-radiographic axial spondyloarthritis patients showed a significant and clinically meaningful reduction in disease activity.
Gilead will now initiate two new clinical trials, for both treatment-naïve and multidrug resistant HIV-1.
The committee initially published a draft final appraisal for the drug in October, and just last week the SMC approved the treatment for use on NHS Scotland.
Patients had 50% fewer flares on the drug compared to placebo.
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
